PT-141 (bremelanotide) is a synthetic peptide studied as a melanocortin-receptor agonist. This guide summarizes what the published scientific literature has examined about PT-141, its molecular profile, and how it is handled in a research setting. It is written for researchers and is not medical guidance.
What is PT-141?
PT-141 (also known as bremelanotide; CAS 189691-06-3; molecular formula C50H68N14O10; molar mass ≈ 1025.2 g/mol) is a cyclic seven-amino-acid peptide and a metabolite of the earlier research compound melanotan II. In research models it is studied as an agonist of melanocortin receptors. The active compound has been approved by regulators as a prescription medicine for a specific clinical indication, but the material supplied here is intended strictly for laboratory research and is not for human use.
Research-use note: PT-141 is supplied strictly for laboratory research. It is not a supplement and not for human or animal consumption. Nothing below describes or endorses human use.
How PT-141 works (the mechanism studied)
PT-141 is characterized in the literature as a non-selective melanocortin-receptor agonist, with research attention focused on its activity at the melanocortin-4 receptor (MC4R) in the central nervous system. Unlike vascular-acting compounds, its mechanism of interest in the literature is centrally mediated — a distinction researchers have studied in detail.
What researchers have studied
The published record on PT-141 consists largely of clinical-trial data. The most-cited studies include:
- Early pharmacology — Diamond et al. (2006) examined the subjective response associated with bremelanotide (PT-141) as a melanocortin-receptor agonist.
- Phase 3 research — Clayton et al. (2019) reported two randomized phase 3 trials (the RECONNECT studies).
- Regulatory overview — review literature (2019) summarized the compound’s development.
These findings belong to the published research record and do not represent approved or validated uses of the research compound sold here.
Handling and reconstitution in the laboratory
PT-141 is typically supplied as a lyophilized powder for research use. Standard laboratory practice is to reconstitute it with bacteriostatic water, swirl (not shake) until dissolved, and store the reconstituted solution refrigerated (2–8 °C). The lyophilized powder is generally stored frozen and protected from light. (General lab-handling notes, not usage instructions.)
For research use only
All products and information referenced here are intended strictly for laboratory and scientific research use only. They are not for human or animal consumption and are not drugs, foods, supplements, or medical devices. No statement here should be interpreted as medical advice.
Explore PT-141 and related research peptides
- PT-141 10mg — verified CAS, formula, and specifications
- Browse all research peptides
- Bacteriostatic Water 30ml — reconstitution diluent
References
- Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. 2006. PubMed
- Clayton AH, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. 2019. PubMed
- Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. 2019. PubMed